Immune potential of allogeneic equine induced pluripotent stem cells.
Authors: Aguiar C, Theoret C, Smith O, Segura M, Lemire P, Smith L C
Journal: Equine veterinary journal
Summary
# Editorial Summary: Immune potential of allogeneic equine induced pluripotent stem cells Regenerative medicine using induced pluripotent stem cells (iPSC) offers considerable promise for treating equine musculoskeletal and soft tissue injuries, yet their immunogenicity—and therefore suitability for allogeneic transplantation—remained poorly understood in large animals. Aguiar and colleagues characterised MHC expression on equine iPSC and compared these cells to their differentiated counterparts and primary fibroblasts, using flow cytometry and immunofluorescence analysis. Equine iPSC demonstrated significantly downregulated MHC class I and class II expression relative to differentiated cells, a finding consistent with observations in human and murine models but previously undocumented in horses. This reduced immunogenicity profile suggests allogeneic equine iPSC may evade host immune rejection more effectively than conventional cell therapies, substantially broadening their potential application in clinical regenerative medicine without requiring immunosuppression. For practitioners considering stem cell therapy options, these findings indicate iPSC warrants serious consideration as a platform for off-the-shelf cellular therapeutics, though further investigation into in vivo immune responses and long-term transplant outcomes remains essential before widespread clinical adoption.
Read the full abstract on PubMed
Practical Takeaways
- •iPSC-based regenerative therapies for horses may be feasible if immune properties align with human/murine findings, potentially allowing allogeneic cell transplantation without rejection
- •Current understanding of iPSC immunogenicity does not extend to equine models, limiting clinical translation decisions for equine practitioners at this time
- •Future research must characterize equine iPSC MHC expression to determine whether donor-recipient matching will be necessary for therapeutic applications
Key Findings
- •Study examined MHC expression on allogeneic equine iPSC to assess transplantation safety
- •No prior data existed on iPSC antigenicity in large animal models before this work
- •Human and murine iPSC show downregulated MHC expression, suggesting potential for safe transplantation
- •Equine iPSC antigenicity characteristics remained to be determined by this research